

Sprint Bioscience recruits Niklas Axelsson as new CFO

Sprint Bioscience today announced that Niklas Axelsson has been appointed as CFO. With over 25 years of experience in both the pharmaceutical industry and the finance sector, Niklas Axelsson will also join the company's management team.

Niklas Axelsson brings extensive experience from nearly 20 years at AstraZeneca, where he held senior financial positions both in Sweden and internationally. Most recently, he served as CFO at the life science company ETAC. Prior to AstraZeneca, he worked in corporate finance at Danske Bank.

"With his unique expertise from both the pharmaceutical and finance sectors, Niklas Axelsson will play a crucial role in strengthening the company and supporting our continued growth. I am very pleased to welcome Niklas to our team," said Johan Emilsson, CEO of Sprint Bioscience.

"I look forward to joining Sprint Bioscience. With its strong pipeline and innovative research portfolio, I see great opportunities to contribute to the company's success and create value for both shareholders and other stakeholders," said Niklas Axelsson, incoming CFO of Sprint Bioscience.

Niklas Axelsson will start his position as CFO at Sprint Bioscience on October 16 and immediately join the company's management team. He will replace Mathias Skalmstad, who, after a handover period, will leave the company for a new role in another organization, as previously announced.

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website: www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

Attachments

[Sprint Bioscience recruits Niklas Axelsson as new CFO](#)